About the 14th Cancer Crosslinks
Networking Event: Thursday, June 16, 2022, 2-4pm (CET)
The January 2022 networking event was rescheduled to June 16, 2022 due to the pandemic. An invitation to join:
Daytime Education Program: Thursday, January 27, 2022
(Daytme Program presented January 2022, information below. The Networking Event will be June 16, 2022).
Getting Ahead of Tumor Evolution -
Changing the Premises in the War Against Cancer
Cancer Crosslinks 2022 gathered distinguished speakers from the UK, USA, Germany,
Switzerland, Canada, and Norway to discuss recent progress in the understanding of tumor evolution
and emerging diagnostic and treatment options for solid and hematological cancers.
The event was presented as an On-site & Digital Event streamed from Oslo.
A Message to Cancer Crosslinks 2022 Attendees:
Thank you for joining Cancer Crosslinks 2022. A special thank you to the international speakers and Norwegian moderators who shared their insights and contributed to an engaging and insightful dialog.
Videos from the speaker presentations will be available until June 20, 2022.
To watch Cancer Crosslinks 2022, please click HERE
Switzerland, Canada, and Norway to discuss recent progress in the understanding of tumor evolution
and emerging diagnostic and treatment options for solid and hematological cancers.
The event was presented as an On-site & Digital Event streamed from Oslo.
A Message to Cancer Crosslinks 2022 Attendees:
Thank you for joining Cancer Crosslinks 2022. A special thank you to the international speakers and Norwegian moderators who shared their insights and contributed to an engaging and insightful dialog.
Videos from the speaker presentations will be available until June 20, 2022.
To watch Cancer Crosslinks 2022, please click HERE
Event 2022 - International Speakers
Mariam Jamal-Hanjani, Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute. Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital. Visiting Scientist, The Francis Crick Institute, London, UK
David Rimm, Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology),
Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
Martin Schuler, Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital,
Essen, Germany
Angela George, Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology,
Royal Marsden Hospital, London, UK
Christoph Driessen, Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Bertrand Routy, Assistant Professor of Hemato-Oncology, Centre de recherche,
Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
David Rimm, Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology),
Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
Martin Schuler, Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital,
Essen, Germany
Angela George, Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology,
Royal Marsden Hospital, London, UK
Christoph Driessen, Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Bertrand Routy, Assistant Professor of Hemato-Oncology, Centre de recherche,
Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
Event 2022 - Topics
Tracking Lung Cancer Evolution from Early to Late-Stage Disease - Its Clinical
and Therapeutic Implications, Mariam Jamal-Hanjani, UCL Cancer Institute London, UK
Current and Future Methods of Predicting Response to Immunotherapy,
David Rimm, Yale University School of Medicine, New Haven, USA
Immunotherapy Trials in the Perioperative Setting - Opportunity for Clinical Proof-of-Concept
and Mechanistic Exploration, Martin Schuler, Partner Site University Hospital Essen, Germany
Precision Therapy for Gynecological Cancers with Focus on Endometrial
(Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options,
Angela George, Royal Marsden Hospital, London, UK
Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors
(The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact),
Christoph Driessen, Kantonsspital St. Gallen, St Gallen, Switzerland
Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics,
Bertrand Routy, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
and Therapeutic Implications, Mariam Jamal-Hanjani, UCL Cancer Institute London, UK
Current and Future Methods of Predicting Response to Immunotherapy,
David Rimm, Yale University School of Medicine, New Haven, USA
Immunotherapy Trials in the Perioperative Setting - Opportunity for Clinical Proof-of-Concept
and Mechanistic Exploration, Martin Schuler, Partner Site University Hospital Essen, Germany
Precision Therapy for Gynecological Cancers with Focus on Endometrial
(Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options,
Angela George, Royal Marsden Hospital, London, UK
Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors
(The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact),
Christoph Driessen, Kantonsspital St. Gallen, St Gallen, Switzerland
Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics,
Bertrand Routy, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
Event 2022 - Moderators from Norway
Kristina Lindemann, Head of Research, Dept. of Gynecological Oncology, Oslo University Hospital
Åsmund Flobak, Oncologist St. Olavs Hospital, Trondheim University Hospital and Researcher, Norwegian University of Science and Technology (NTNU)
Tobias Schmidt Slørdahl, Associate Professor/Resident, St. Olavs Hospital,
Trondheim University Hospital
Åsmund Flobak, Oncologist St. Olavs Hospital, Trondheim University Hospital and Researcher, Norwegian University of Science and Technology (NTNU)
Tobias Schmidt Slørdahl, Associate Professor/Resident, St. Olavs Hospital,
Trondheim University Hospital
Event 2022 - Reference Materials
The Invitation (with Program included) may be downloaded HERE.
The Program may be downloaded HERE.
The Brochure (digital format & print-friendly) may be downloaded HERE.
The Program may be downloaded HERE.
The Brochure (digital format & print-friendly) may be downloaded HERE.
|
Organizer
|
Sponsors 2022
|
|
|
|
To learn more about previous Cancer Crosslinks events, visit the GALLERY.